AGÕæÈ˹ٷ½

STOCK TITAN

Inspira Secures $27 Million Government Binding Purchase Order for ART100 Systems with Full Payment in 2025

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Inspira Technologies (NASDAQ: IINN) has secured a significant $27 million binding purchase order from an African national ministry of health for its FDA-cleared ART100 systems. The order, obtained through an exclusive distribution partner, includes full payment scheduled for completion in 2025.

This strategic breakthrough brings Inspira's total secured binding purchase orders for 2025 to $49.5 million. The nationwide deployment program includes installation, training, and onboarding services. The selection of ART100 was based on its proven performance in U.S. Tier-1 hospitals and its capability to strengthen national emergency and critical care infrastructure.

Inspira Technologies (NASDAQ: IINN) ha ottenuto un ordine di acquisto vincolante da 27 milioni di dollari da un ministero della salute nazionale africano per i suoi sistemi ART100 approvati dalla FDA. L'ordine, acquisito tramite un distributore esclusivo, prevede il pagamento integrale previsto per il completamento nel 2025.

Questa svolta strategica porta gli ordini di acquisto vincolanti complessivamente assicurati da Inspira per il 2025 a 49,5 milioni di dollari. Il programma di distribuzione nazionale comprende installazione, formazione e servizi di onboarding. La scelta dell'ART100 è stata motivata dalle sue prestazioni comprovate negli ospedali Tier-1 statunitensi e dalla capacità di rafforzare l'infrastruttura nazionale di emergenza e cure critiche.

Inspira Technologies (NASDAQ: IINN) ha asegurado una orden de compra vinculante de 27 millones de dólares por parte de un ministerio de salud nacional africano para sus sistemas ART100 autorizados por la FDA. La orden, obtenida a través de un distribuidor exclusivo, incluye el pago completo programado para completarse en 2025.

Este avance estratégico eleva las órdenes de compra vinculantes aseguradas por Inspira para 2025 a un total de 49,5 millones de dólares. El programa de implementación a nivel nacional incluye instalación, capacitación y servicios de incorporación. La selección del ART100 se basó en su rendimiento demostrado en hospitales Tier-1 de EE. UU. y en su capacidad para fortalecer la infraestructura nacional de emergencias y cuidados críticos.

Inspira Technologies (NASDAQ: IINN)ëŠ� FDA ìŠ¹ì¸ ART100 ì‹œìŠ¤í…œì— ëŒ€í•� 아프리카ì� í•� 보건부로부í„� 2,700ë§� 달러 규모ì� 구ì†ë � 있는 구매 주문ì� 확보했습니다. 해당 ì£¼ë¬¸ì€ ë…ì  ìœ í†µ 파트너를 통해 ì´ë£¨ì–´ì¡Œìœ¼ë©°, ì „ì•¡ ê²°ì œëŠ� 2025ë…� 완료ë� 예정입니ë‹�.

ì´ë²ˆ ì „ëžµì � 성과ë¡� Inspiraê°€ 2025ë…� 확보í•� ì´� 구ì†ë � 있는 구매 ì£¼ë¬¸ì•¡ì€ 4,950ë§� 달러가 ë˜ì—ˆìŠµë‹ˆë‹�. ì „êµ­ 단위 배치 프로그램ì—는 설치, êµìœ¡ ë°� 온보ë”� 서비스가 í¬í•¨ë©ë‹ˆë‹�. ART100ì€ ë¯¸êµ­ Tier-1 병ì›ì—서 ìž…ì¦ë� 성능ê³� êµ­ê°€ì � ì‘급·중환ìž� 치료 ì¸í”„ë¼ë¥¼ ê°•í™”í•� ìˆ� 있는 능력으로 ì„ ì •ë˜ì—ˆìŠµë‹ˆë‹�.

Inspira Technologies (NASDAQ: IINN) a obtenu un bon de commande contraignant de 27 millions de dollars de la part d'un ministère national de la santé africain pour ses systèmes ART100 homologués par la FDA. La commande, obtenue via un distributeur exclusif, prévoit un paiement intégral devant être effectué d'ici 2025.

Cette avancée stratégique porte le total des bons de commande contraignants sécurisés par Inspira pour 2025 à 49,5 millions de dollars. Le programme de déploiement national comprend l'installation, la formation et les services d'intégration. Le choix de l'ART100 s'est appuyé sur ses performances avérées dans des hôpitaux Tier-1 aux États-Unis et sur sa capacité à renforcer l'infrastructure nationale d'urgence et de soins critiques.

Inspira Technologies (NASDAQ: IINN) hat einen bedeutenden verbindlichen Kaufauftrag über 27 Millionen US-Dollar von einem afrikanischen Gesundheitsministerium für seine FDA-zugelassenen ART100-Systeme erhalten. Der Auftrag, der über einen exklusiven Vertriebspartner eingeworben wurde, sieht eine vollständige Zahlung vor, die bis 2025 abgeschlossen sein soll.

Dieser strategische Durchbruch erhöht die von Inspira für 2025 gesicherten verbindlichen Kaufaufträge auf insgesamt 49,5 Millionen US-Dollar. Das landesweite Einführungsprogramm umfasst Installation, Schulung und Onboarding-Services. Die Wahl des ART100 basierte auf seiner nachgewiesenen Leistung in US-Tier-1-Krankenhäusern und seiner Fähigkeit, die nationale Notfall- und Intensivversorgungsinfrastruktur zu stärken.

Positive
  • Secured substantial $27 million binding purchase order from government entity
  • Total binding purchase orders for 2025 reached $49.5 million
  • Full payment guaranteed during 2025, ensuring revenue acceleration
  • Validation of commercial strategy through government contract
  • Proven market acceptance with successful deployment in U.S. Tier-1 hospitals
Negative
  • Dependence on single large government contract for significant revenue
  • Execution risk associated with nationwide deployment program
  • Geographic concentration risk in African market

Insights

Inspira secures significant $27M government order for ART100 systems, boosting 2025 confirmed orders to $49.5M with full payment expected this year.

This $27 million binding purchase order from an African ministry of health represents a major commercial milestone for Inspira Technologies. The order specifically targets their FDA-cleared ART100 systems, marking their second significant contract in rapid succession. Combined with previous orders, Inspira has now secured $49.5 million in binding purchase orders for 2025, suggesting strong market traction for their life-support technology.

What makes this deal particularly noteworthy is the payment structure � full contractual payment is scheduled for completion during 2025, providing immediate revenue recognition and strengthening Inspira's financial position. This accelerated payment term demonstrates unusual confidence from the government buyer, which typically negotiate extended payment schedules.

The purchase was facilitated through Inspira's exclusive distribution partner, highlighting their effective go-to-market strategy using specialized distribution channels. According to the release, the ministry selected the ART100 based on its performance in Tier-1 U.S. hospitals, suggesting their technology has established credibility in sophisticated healthcare markets before expanding to emerging ones.

With a nationwide deployment program initiated immediately, Inspira must now execute on delivery, installation, training, and customer onboarding � all critical elements for maintaining momentum and securing additional orders. The CEO's statement that additional orders are expected suggests their sales pipeline remains active beyond this significant deal.

RA'ANANA, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inspiraâ„� Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (â€�Inspira,â€� â€Àá²Ô²õ±è¾±°ù²¹ Technologies,â€� or the â€�Companyâ€�), a pioneer in innovative life-support and diagnostic technologies, today announced that a national ministry of health in Africa   (the “Ministry of Healthâ€�) has placed a $27 million binding purchase order for Inspira’s FDA-cleared ART100 systems. The purchase order, secured through Inspira’s exclusive distribution partner, dedicated solely to the commercialization of Inspira’s products, initiates an immediate nationwide deployment program.

The purchase order provides for full contractual payment scheduled for completion during 2025. This structure underscores the Ministry’s commitment and will accelerate revenue for Inspira. Shipments will be scheduled in coordination with the Ministry of Health, with installation, training, and onboarding to follow.

"This $27 million government purchase order is a strategic breakthrough that is a validation of our  commercial model," said Dagi Ben-Noon, CEO of Inspira Technologies. "We are now executing our commercial strategy with full force across multiple fronts. This is the second significant order we have secured in a short period of time, bringing our total secured binding purchase orders for 2025 to $49.5 million. This order continues the momentum we promised our shareholders, with additional orders expected to follow.�

The Ministry of Health mentioned selected the ART100 based on its proven performance in Tier-1 hospitals in the U.S. and its ability to reinforce national emergency and critical care infrastructure. Deliveries are expected to continue throughout 2025 under a nationwide roll-out schedule.

About Inspira Technologies

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA� ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA�, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the full contractual payment scheduled for completion during 2025, that the order underscores the Ministry’s commitment and will accelerate revenue for Inspira, the timing of the delivery of the first shipments, as well as the installation, training and onboarding relating to the order, that the order is a strategic breakthrough that is a validation of its commercial model, that it is executing its commercial strategy with full force across multiple fronts, the total of its binding orders received in 2025, that the order continues the momentum it promised its shareholders, with additional orders expected to follow, and that deliveries are expected to continue throughout 2025 under a nationwide roll-out schedule. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at .

Company Contact
Inspira Technologies � Media Relations
Email: [email protected]
Phone: +972-9-9664485


FAQ

What is the value of Inspira Technologies' (IINN) new purchase order in 2025?

Inspira Technologies secured a $27 million binding purchase order from an African national ministry of health for its ART100 systems.

What is Inspira Technologies' (IINN) total order value for 2025?

Inspira Technologies has secured total binding purchase orders of $49.5 million for 2025, including this latest $27 million order.

When will Inspira Technologies (IINN) receive payment for the $27M order?

The purchase order provides for full contractual payment scheduled for completion during 2025.

What product is included in Inspira Technologies' (IINN) $27M government order?

The order is for Inspira's FDA-cleared ART100 systems, selected based on their proven performance in U.S. Tier-1 hospitals.

How will Inspira Technologies (IINN) implement the $27M government contract?

Implementation includes a nationwide deployment program with scheduled shipments, installation, training, and onboarding services coordinated with the Ministry of Health.
Inspira Technologies Oxy Bhn Ltd

NASDAQ:IINN

IINN Rankings

IINN Latest News

IINN Stock Data

37.90M
23.38M
8.75%
4.39%
1.5%
Medical Devices
Healthcare
Israel
Ra'anana